生物技术公司Moderna, Inc. (MRNA) 今日盘中股价大幅上涨6.06%，成为市场关注的焦点。
消息面上，Moderna与默沙东联合公布了其个体化mRNA癌症疫苗intismeran autogene（V940）的2b期临床试验五年随访数据。结果显示，该疫苗与Keytruda联合疗法在高风险黑色素瘤患者中，将复发或死亡风险显著降低了49%。这一积极数据进一步验证了mRNA技术在肿瘤免疫治疗领域的巨大潜力，增强了市场对公司长期发展的信心。
目前，该联合疗法已获得美国FDA的突破性疗法认定和欧洲EMA的PRIME资格，并有八项2/3期临床试验正在进行中，覆盖多种癌症适应症。分析认为，这一进展巩固了Moderna在mRNA治疗领域的领先地位，是推动股价上涨的直接催化剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.